Sherwin-Williams has underperformed the broader market over the past year, and yet, analysts remain moderately optimistic ...

Investing.com -- UBS in a note dated Thursday upgraded PolyPeptide Group AG (SIX:PPGN) to a “buy” rating from “neutral” following progress at its Braine-l’Alleud site. Shares of the Swiss company were ...